ReviewComputational and structural biotechnology journal2025
Bacteriophage-based strategies for biocontrol and treatment of infectious diseases.
Review in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Isolation and characterization of novel phages for control of the phytopathogen Pseudomonas marginalis.Applied microbiology and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophages are viruses that infect bacteria, which are essential for controlling bacterial diversity. Among the novel aspects, phage display-based strategies are used for epitope mapping and the development of immunotherapy. A recent classification system has been developed based on the recent sequencing methods and bioinformatic tools. The unique specificity of phages is of increasing use in biocontrol, where bacteriophages are applied to target and reduce harmful bacterial populations in agriculture, food preservation and safety, offering a sustainable alternative to chemical exposure and a plausible solution to excessive misuse of antibiotics. Phage therapy has emerged as a complement to antibiotics for difficult-to-treat infectious diseases such as multi-drug resistant bacteria where other alternatives are lacking. The ability of bacteriophages to specifically target pathogenic bacteria while sparing the normal flora makes them attractive treatment options. Among the challenges are the slow uptake of phage therapy in the clinical setting, a lack of standardisation and regulatory issues. Nevertheless, phage-based strategies are likely to become a future cornerstone for biocontrol and treatment of infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.